To provide physicians with current information on emerging trends in the treatment of cardiovascular disease (CVD) in postmenopausal women.
This activity is designed for obstetricians, gynecologists, primary care physicians, pharmacy and therapeutic committee members, and managed care decision makers working in the area of women's health.
After reading this issue, the participant should be able to:
- Describe the latest developments in the prevention of CVD in postmenopausal women, with reference to the HERS II, WHI, and MORE study.
- Identify the cardiovascular risk factors associated with postmenopausal women.
- Understand the effect of the latest therapies on cardiovascular risk factors in the postmenopausal population.
This activity has been planned and produced in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 hours in Category 1 credit toward the American Medical Association (AMA) Physicians' Recognition Award. Each physician should only claim those hours of credit that he/she actually spends in this educational activity. Credits are available until the expiration date of October 31, 2004.
This continuing education activity was produced under the supervision of Roger S. Blumenthal, MD, Director, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and Associate Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine.
This program is approved for 2 hours of credit (0.2 CEUs) and is cosponsored by The University of Tennessee College of Pharmacy, which is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. ACPE Program #064-999-02-244-H01. Credits are available until the expiration date of October 31, 2004.
This continuing pharmacy education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean of Continuing Education, University of Tennessee College of Pharmacy.
This program is supported by an unrestricted educational grant from Eli Lilly and Company.
Publisher's Note and Disclaimer: The opinions expressed in this issue are those of the authors, presenters, and/or panelists and are not attributable to the publisher, editor, advisory board of Advanced Studies in Medicine, or The Johns Hopkins University School of Medicine or its Office of Continuing Medical Education. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this issue are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Advanced Studies in Medicine (ISSN-1530-3004) is published by Galen Publishing, LLC, an HMG Company. P.O. Box 340, Somerville, NJ 08876. (908) 253-9001. Web site: www.galenpublishing.com. Copyright ©2001 by Galen Publishing, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. Bulk postage paid at Somerville, NJ Post Office and at additional mailing offices. Advanced Studies in Medicine is a registered trademark of The Healthcare Media Group, LLC. Printed on acid-free paper. BPA Membership applied for December 2000.